Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded...

Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded...

Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type

SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 80,000 samples received to date for...

Biocept Provides Update on COVID-19 Testing with More than 80,000 Samples Received

SAN DIEGO, Sept. 4, 2020 /PRNewswire/ -- Biocept, Inc.

Biocept Announces One-for-Ten Reverse Stock Split

SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- Biocept, Inc.

Biocept Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More than 20,000 Specimens Processed

SAN DIEGO, Aug.  24, 2020  (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the appointment of Michael C. Dugan, M.D. as Chief Medical Officer and Medical Director.  Dr. Dugan has served in leading medical positions at Exact Sciences, Quest Diagnostics, Nichols Institute and Roche Molecular Systems.  At Biocept he will be responsible for medical policy decision-making and the operations of the Company’s CLIA-certified, CAP-accredited, high-complexity molecular laboratory.

Biocept Names Michael Dugan, M.D. Chief Medical Officer and Medical Director

SAN DIEGO, Aug.  20, 2020  (GLOBE NEWSWIRE) --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the Proactive One2One Virtual Investor Forum, North America on Tuesday, August 25 at 1:00 p.m. Eastern time (10 a.m. Pacific time). 

Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25

SAN DIEGO, Aug.  19, 2020  (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the expansion of its agreement with MultiPlan, Inc. to include COVID-19 testing services at a pre-negotiated price per test. MultiPlan is a healthcare cost management company offering payment integrity, network-based and analytics-based services. With the expanded agreement, Biocept’s COVID-19 testing, in addition to its liquid biopsy oncology testing services, are now accessible to consumers who have access to the PHCS and MultiPlan Networks, MultiPlan’s national primary and complementary networks. More than 1 million healthcare providers participate in MultiPlan’s networks and 60 million health plan members have access to the company’s services.

Biocept Expands Agreement with MultiPlan to Include COVID-19 Testing

Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2020 Results - Earnings Call Transcript

SAN DIEGO, Aug. 12, 2020 /PRNewswire/ -- Biocept, Inc.

Biocept Reports Second Quarter 2020 Financial Results

Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.

Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?

SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Biocept, Inc.

Biocept Announces Agreement with Aegea Biotechnologies to Develop New, Highly Sensitive PCR-based COVID-19 Assay Utilizing Patented Switch-Blocker PCR Technology

SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Biocept, Inc.

Biocept Reaches COVID-19 Testing Milestone with More than 7,000 Specimens Received and More than 6,500 Specimens Processed

Ampio Pharmaceuticals Inc

Boxlight

eMagin

These seven penny stocks have the right catalysts, business models, and tailwinds. Read about why the risk is worth it.

7 Penny Stocks Worth the Danger as Pandemic Catalyzes Growth

SAN DIEGO, July 16, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that Institutional Shareholder.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Support Biocept Proposal to Authorize the Reverse Split of Common Shares

SAN DIEGO, June 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it has been awarded Canadian...

Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid

SAN DIEGO, June 24, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces it has entered into a managed...

Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims

SAN DIEGO, June 22, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000...

Biocept Announces the Availability of 10,000 Specimen Collection Kits for RT-PCR COVID-19 Testing

SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its...

Biocept to Relocate Corporate Offices and CLIA-Certified Laboratory to New San Diego Location

SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Nall,...

Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020

SAN DIEGO, May 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of a...

Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories

Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2020 Results - Earnings Call Transcript

Athersys

BioCryst Pharmaceuticals

Can-Fite BioPharma Ltd.

As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.

Biocept To Begin COVID-19 Testing Wednesday, BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics

Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript

Shares of Biocept Inc. BIOC, -42.27% plummeted 42% on very heavy volume in morning trading Monday, after the provider of liquid cancer tests announced the pricing of stock offering at a deep discount.

News for Biocept Stock (BIOC)